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The T-cell immunoglobulin mucin 1 (Tim-1) modulates
CD4þ T-cell responses and is also expressed by damaged
proximal tubules in the kidney where it is known as kidney
injury molecule-1 (Kim-1). We sought to define the role
of endogenous Tim-1 in experimental T-cell–mediated
glomerulonephritis induced by sheep anti-mouse glomerular
basement membrane globulin acting as a planted foreign
antigen. Tim-1 is expressed by infiltrating activated CD4þ
cells in this model, and we studied the effects of an inhibitory
anti-Tim-1 antibody (RMT1-10) on immune responses and
glomerular disease. Crescentic glomerulonephritis,
proliferative injury, and leukocyte accumulation were
attenuated following treatment with anti-Tim-1 antibodies,
but interstitial foxp3þ cell accumulation and interleukin-10
mRNA were increased. T-cell proliferation and apoptosis
decreased in the immune system along with a selective
reduction in Th1 and Th17 cellular responses both in the
immune system and within the kidney. The urinary excretion
and renal expression of Kim-1 was reduced by anti-Tim-1
antibodies reflecting diminished interstitial injury. The effects
of anti-Tim-1 antibodies were not apparent in the early phase
of renal injury, when the immune response to sheep globulin
was developing. Thus, endogenous Tim-1 promotes Th1 and
Th17 nephritogenic immune responses and its neutralization
reduces renal injury while limiting inflammation in
cell-mediated glomerulonephritis.
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Crescentic glomerulonephritis is characterized by prolifera-
tive lesions, and at times by necrotizing glomerular lesions,
and glomerular crescent formation with mononuclear cell
infiltration both in the glomeruli and the tubulointerstitium.
Experimentally, some forms are mediated by cell-mediated
immunity, with effector cellular immune responses including
T helper type 1 (Th1) cells that direct the recruitment of
macrophages1–3 and Th17 responses. Injury is attenuated
by Th2 cytokines4–6 and endogenous regulatory T cells,7 but
is independent of CD8þ T cells,8 B cells, and autologous
antibodies.9
The T-cell immunoglobulin mucin domain (Tim) family
consists of eight genes in mice and three in humans. Tim
family members are cell-surface glycoproteins sharing common
motifs, including an IgV domain, a mucin-like domain, a
transmembrane domain, and intracellular tail.10,11 In the
immune system, Tim proteins can regulate or promote T-cell
activation. They are expressed on Th cells (and dendritic cells,
in the case of Tim-4) and have been implicated in
immunopathology.12,13 Tim-1 is expressed on activated T cells
and, upon CD4þ T-cell polarization, on both Th2 and Th1
cells.14,15 It promotes activated T cells’ survival.16
Although Tim-1 is expressed in the immune system, it is
also expressed by injured tubules, where it is known as kidney
injury molecule-1 (Kim-1). Although Kim-1 is undetectable
in normal kidneys, it is induced in ischemic,17 toxic,18 and
proteinuric renal disease.19 Its renal expression has been
associated with the dedifferentiation of epithelial cells,17 and
Kim-1 allows tubular cells to participate in the phagocytosis
of apoptotic debris via recognizing phosphatidylserine.20
Given the role of effector T cells in crescentic glomer-
ulonephritis, the current studies addressed the hypothesis
that inhibiting Tim-1 would ameliorate experimental cres-
centic glomerulonephritis. To test this hypothesis, we inhi-
bited Tim-1 using an antagonistic monoclonal antibody,
RMT1-10,21 in a well-characterized murine model of
crescentic glomerulonephritis induced by injecting sheep
anti-mouse glomerular basement membrane (anti-GBM)
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antibodies. After initial injury mediated by anti-GBM anti-
bodies as antibodies (the heterologous phase), an ‘auto-
logous’ CD4þ cell–mediated response develops against
sheep globulin as a planted foreign antigen, causing
proliferative and crescentic glomerulonephritis.
RESULTS
Endogenous Tim-1 promotes experimental crescentic
glomerulonephritis
Control mice given sheep anti-mouse GBM globulin (with-
out prior sensitization) and nonimmune rat (r)IgG devel-
oped proteinuria within 24 h (the disease’s heterologous
phase) and by day 14 (when injury is directed by autologous
responses against sheep globulin) proliferative glomerulo-
nephritis with segmental necrosis and crescent formation
(Figure 1), proteinuria, and an increased serum creatinine.
Mice were treated with an anti-Tim-1 antibody (‘Anti-Tim-
1’) to inhibit the effects of Tim-1 from the initiation of
disease. Renal injury at day 14 (rat IgG, n¼ 7; anti-Tim-1,
n¼ 8) was attenuated in anti-Tim-1 antibody–treated
nephritic mice, with fewer glomerular crescents (rIgG,
15.6±3.9; anti-Tim-1, 4.8±2.3%), less interstitial injury
(rIgG, 2.9±0.6; anti-Tim-1, 1.3±0.2 (score 0–3þ )), less
proteinuria (rIgG, 13.5±1.4; anti-Tim-1, 4.9±2.2mg/day)
and a trend to a lesser rise in serum creatinine levels (rIgG,
32±4; anti-Tim-1, 23±2mmol/l, Figure 1). Heterologous
injury was unaffected, with proteinuria unchanged at day 1
(n¼ 7 for both groups; rIgG 11.0±2.0; anti-Tim-1,
7.4±2.0mg/day). Glomerular leukocyte accumulation was
reduced in anti-Tim-1 antibody–treated mice on day 14
(CD4þ cells: rIgG, 0.8±0.2; anti-Tim-1, 0.4±0.1; macro-
phages: rIgG, 1.5±0.1; anti-Tim-1, 0.3±0.1; neutrophils:
rIgG, 0.7±0.2; anti-Tim-1 0.3±0.1 cells/glomerular cross-
section (c/gcs); Figure 2a–c). Interstitial CD4þ cell (rIgG,
1.3±0.2; anti-Tim-1, 0.5±0.1 cells/high-power field (c/hpf))
and macrophage (rIgG, 2.1±0.4; anti-Tim-1, 0.9±0.1 c/hpf)
numbers were reduced but neutrophils (rIgG, 2.8±0.6; anti-
Tim-1, 2.0±0.3 c/hpf) were not (Figure 2d–f). Numbers of
intrarenal foxp3þ regulatory T cells (Tregs), found only in
the tubulointerstitium, were increased in mice given anti-
Tim-1 antibodies (rIgG, 2.7±0.5; anti-Tim-1, 5.9±0.3 c/hpf;
foxp3 mRNA rIgG, 4.2±0.5; anti-Tim-1, 10.0±2.4-fold
increase over normal mice; Figure 2g–j). Treatment reduced
proliferation (Ki-67 immunostaining) within glomeruli
(rIgG, 2.0±0.3; anti-Tim-1, 1.0±0.4 c/gcs) and the tubu-
lointerstitium (rIgG, 16.7±3.2, anti-Tim-1, 5.9±2.4 c/hpf;
Figure 3a–f). Cleaved caspase-3þ apoptotic cells on day 14
were not detected in glomeruli, but apoptosis was reduced in
the tubulointerstitium after anti-Tim-1 antibodies (rIgG,
2.1±0.4; anti-Tim-1, 1.0±0.3 c/hpf; Figure 3g–i).
Anti-Tim-1 antibodies limit Th1 and Th17 responses, but not
Th2 responses
Systemic immune responses 14 days (rIgG n¼ 7; anti-Tim-1
n¼ 8) after the induction of glomerulonephritis showed that
compared with rIgG-injected mice with glomerulonephritis,
splenic CD4þ T-cell proliferation (rIgG, 11.8±0. 3; anti-
Tim-1, 6.9±0.3%; Figure 4a) and CD4þ T-cell apoptosis
(rIgG, 8.5±0.6; anti-Tim-1, 6.6±0.4%; Figure 4b) were
suppressed in anti-Tim-1 antibody–treated mice. There were
fewer interferon-gamma (IFN-g)–producing splenic CD4þ
cells (rIgG 4.1±0.4, anti-Tim-1 2.2±0.1%; Figure 4c) and a
trend to decreased proportions of interleukin (IL)-17A–pro-
ducing cells (rIgG, 0.53±0.21; anti-Tim-1, 0.10±0.06%;
Figure 4d). Proportions of IL-4–producing CD4þ cells were
below the level of detection of the assay. The proportion of
CD4þ cells that were also foxp3þCD25þ , was similar in
both groups (rIgG, 4.9±0.3; anti-Tim-1, 4.7±0.5%).
Expression of mRNA for Th-cell subset transcription
factors, T-bet (Th1), GATA-3 (Th2), RORg (Th17), and
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Figure 1 |Anti-T-cell immunoglobulin mucin 1 (Tim-1)
antibodies reduce the severity of experimental crescentic
glomerulonephritis. Representative photomicrographs of
glomerular cross-sections at high power,  400, in mice with
glomerulonephritis given (a) rIgG or (b) anti-Tim-1 antibodies.
Nonimmune rat IgG (rIgG)–injected mice developed proliferative
and crescentic glomerulonephritis, which was diminished in
anti-Tim-1 antibody–treated mice (c), with decreased interstitial
disease (d). Compared with that in rIgG-treated mice, proteinuria
(e) in anti-Tim-1 antibody–treated mice was not different in the
heterologous phase (day 1) but was decreased at day 14. There
was a trend toward a lesser rise in serum creatinine (f) in anti-
Tim-1 antibody–treated mice. Dotted lines represent mean values
from normal C57BL/6 mice without nephritis. *Po0.05, **Po0.005.
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foxp3 (Tregs), were assessed in splenic mRNA from each
mouse (Table 1). Although both T-bet and RORg mRNA
expressions were reduced in anti-Tim-1–treated mice, GATA3
expression was increased and foxp3 was unaltered. Cytokine
production in sheep globulin–stimulated splenocyte cultures
after 72 h showed reduced IFN-g (rIgG, 1049±36 pg/ml;
anti-Tim-1; 669±138 pg/ml; Figure 5a) and IL-17A (rIgG,
464±97 pg/ml; anti-Tim-1, 246±48 pg/ml; Figure 5b) after
treatment in vivo with anti-Tim-1 antibodies. IL-4 (rIgG,
63±33 pg/ml; anti-Tim-1, 85±28 pg/ml; Figure 5c) and
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Figure 2 |Anti-T-cell immunoglobulin mucin 1 (Tim-1) treatment limits glomerular and interstitial leukocyte accumulation. On day
14, anti-Tim-1 antibody–treated mice had less glomerular leukocyte infiltrates, including fewer CD4þ cells (a), macrophages (b), and
neutrophils (c). Findings for interstitial CD4þ cells (d) and macrophages (e) were similarly reduced in anti-Tim-1 antibody–treated mice, but
interstitial neutrophils were not significantly reduced (f). Interstitial foxp3þ cells, shown as black dots at high power,  400, were detected
in both rat IgG (rIgG) (g)- and anti-Tim-1 antibody–treated mice (h), but anti-Tim-1-treated mice had more foxp3þ positive cells in the
interstitium (i). Foxp3þ cells were not found in glomeruli. Intrarenal foxp3 mRNA expression in anti-Tim-1 antibody–treated mice was
increased compared with rIgG-treated mice (j). Dotted lines represent mean values from normal C57BL/6 mice without nephritis. c/gcs, cells
per glomerular cross-section; c/hpf, cells per high-power field. *Po0.05, **Po0.005.
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IL-10 (rIgG, 27±8 pg/ml; anti-Tim-1, 37±7 pg/ml; Figure
5d) levels were not different between the groups. Antigen-
specific serum IgG (Figure 5e) and IgG1 (rIgG, 0.33±0.02;
anti-Tim-1, 0.47±0.01; Figure 5f) titers were increased in
anti-Tim-1 antibody–treated mice, but IgG3 (rIgG, 0.33±
0.05; anti-Tim-1, 0.28±0.03; Figure 5g) was unchanged.
Therefore, anti-Tim-1 antibodies shifted systemic immune
responses away from a Th1 and Th17 phenotype.
Tim-1 is present on intrarenal CD4þ cells in disease
As injury was reduced by anti-Tim-1 antibodies, we
examined whether Tim-1 was expressed on intrarenal effector
CD4þ cells (CD4þCD44þ ). Flow cytometric analyses of
intrarenal CD4þ cells from normal mice and mice receiving
anti-GBM antibodies alone showed, as anticipated, a
progressive increase in intrarenal CD4þ cells over time
(normal mice (n¼ 4) 46±5, day 6 (n¼ 5) 79±11, day 14
(n¼ 5) 143±18 103 CD4þ cells/kidney; Figure 6a).
Although Tim-1–expressing CD4þ cells were uncommon
in normal kidneys, increasing proportions and numbers of
CD4þCD44þ cells expressed Tim-1 by day 14 (Figure 6b
and c; (%) normal 0.03±0.01, day 6 0.32±0.13, day 14
2.08±0.78% of CD4þ cells that were Tim-1þ ; absolute
numbers 11±4, day 6 277±142, day 14 2402±542 CD4þ
CD44þTim-1þ cells/kidney; flow cytometry plots shown
in Supplementary Figure S1 online). Therefore, anti-Tim-1
antibodies may function locally on CD4þ effector cells, in
addition to their effects on systemic immune responses.
Anti-Tim-1 antibody treatment reduces intrarenal
proinflammatory mediators
Analyses of intrarenal mRNA provided further insights as to
how altered immune responses and reduced leukocyte
recruitment translated into reduced injury (rIgG n¼ 7;
anti-Tim-1 n¼ 8; Figure 7). Renal proinflammatory cytokine
mRNA was reduced in nephritic mice to which anti-Tim-1
antibodies were given. IFN-g (rIgG, 6.7±1.4-fold increase;
anti-Tim-1 3.7±0.5-fold increase over normal mice), IL-17A
(rIgG, 14.3±4.4; anti-Tim-1 1.8±0.7), and IL-1b (rIgG,
22.4±5.1; anti-Tim-1, 9.8±2.2) mRNA expressions were
reduced; there were trends toward reduced IL-12p40,
common to both IL-12 and IL-23 (rIgG, 2.4±1.1; anti-
Tim-1, 0.8±0.3) and tumor necrosis factor (rIgG, 9.5±5.6;
anti-Tim-1, 2.9±0.8) mRNA expressions. Conversely, IL-4
(rIgG, 2.6±0.4; anti-Tim-1, 4.9±1.1) and IL-10 mRNA
(rIgG, 11.5±1.6; anti-Tim-1, 31.9±13.1) were increased.
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Figure 3 |Anti-T-cell immunoglobulin mucin 1 (Tim-1) antibody treatment reduces intrarenal proliferation and apoptosis.
There were more intraglomerular Ki-67þ cells, shown as black dots at high power,  400, in rat IgG (rIgG)-treated mice than in
anti-Tim-1 antibody–treated mice both in the glomerulus (a–c) and in the interstitium (d–f). In comparison with rIgG-treated mice, cleaved
caspase-3þ cells in the tubulointerstitium were reduced in anti-Tim-1 antibody–treated mice (g–i). Cleaved caspase-3þ cells were
not found in glomeruli. Photomicrograhs were taken at high power,  400. *Po0.05.
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There were widespread reductions in intrarenal chemokine
mRNA expression (CCL2, CCL5, CXCL1, CXCL2, and
CXCL9) after anti-Tim-1 treatment (Table 2). CXCL10 and
CCL20 mRNA expressions were unchanged. Intercellular
adhesion molecule-1 (ICAM-1), important in renal leukocyte
recruitment, was also reduced after anti-Tim-1 antibodies
(Figure 8) in both glomerular (rIgG, 2.2±0.3; anti-Tim-1,
1.3±0.3 (score 0–3þ )) and tubulointerstitial compartments
(rIgG, 2.5±0.2; anti-Tim-1, 1.1±0.3), with reduced intra-
renal ICAM-1 mRNA expression (rIgG, 11.8±3.1; anti-
Tim-1, 4.2±0.7).
Renal expression and urinary secretion of Tim-1 (Kim-1)
Tim-1 (as ‘Kim-1’) is expressed by injured tubules. In normal
kidneys, Kim-1 protein was undetectable by immunostaining
(Figure 9a); however, after 14 days of glomerulonephritis,
Kim-1þ proximal tubules were seen with apical and
cytoplasmic staining (Figure 9b). Compared with nephritic
rIgG–treated mice, renal Kim-1 staining was reduced in anti-
Tim-1 antibody–treated mice (Figure 9c). Anti-Tim-1 anti-
bodies limited the increase in intrarenal Kim-1 mRNA
expression seen in control-injected mice with nephritis (rIgG,
132.5±33.4; anti-Tim-1, 47.1±15.2; Figure 9d). Urinary
Kim-1 excretion, assessed by enzyme-linked immunosorbent
assay (Figure 9e), showed that, although urinary Kim-1
was undetectable in mice without glomerulonephritis, in
rIgG-injected mice with glomerulonephritis urinary Kim-1
increased from days 1 to 14. Urinary Kim-1 levels in anti-
Tim-1 antibody–treated mice were similar on day 1 (rIgG,
1.5±0.9 ng/day; anti-Tim-1 0.7±0.6 ng/day), but by day 14
levels did not rise as high as in nephritic rIgG–injected mice
(rIgG 7.9±1.7 ng/ml; anti-Tim-1 2.5±1.0 ng/ml). Kim-1
protein expression (at day 14 by western blotting; Figure 9f
and g) showed undetectable Kim-1 protein in normal mouse
kidneys, renal Kim-1 expression at day 14 in rIgG-injected
mice, and reduced Kim-1 protein in anti-Tim-1-treated mice
(rIgG, 0.24±0.07; anti-Tim-1, 0.08±0.05 (ratio Kim-1/
b-actin density)).
Binding of anti-Tim-1 antibodies to tubular cells in vivo
The RMT1-10 antibody used in these studies does not affect
Tim-1–mediated binding of apoptotic cells;22 however, to
determine whether it can bind to Kim-1 on tubular cells
in vivo, anti-rat IgG antibodies were applied to kidney sections.
Although rat IgG was not detected in control mice with
glomerulonephritis (mice not injected with rat IgG) or in mice
with glomerulonephritis injected with nonimmune rIgG, mice
receiving the rat anti-mouse-Tim-1 antibody RMT1-10 did
show binding of rat IgG (i.e., RMT1-10) to the luminal surface
of tubular cells, focally within the tubulointerstitium, at days 6
and 14 (Supplementary Figure S2 online).
Anti-Tim-1 antibodies do not affect early injury
Immune responses and renal disease were studied 6 days after
the induction of glomerulonephritis, early in the autologous
phase. Proteinuria (rIgG, 11.4±1.6mg/day; anti-Tim-1,
10.6±1.9mg/day), serum creatinine values (rIgG, 19.6±
2.5 mmol/l; anti-Tim-1, 17.3±2.1 mmol/l), the proportion
of abnormal glomeruli (rIgG, 51.8±2.1%; anti-Tim-1,
50.1±1.1%), and the mild tubulointerstitial injury (rIgG,
0.7±0.04; anti-Tim-1, 0.6±0.03 (score 0–4þ )) were similar
in anti-Tim-1– and rIgG–injected mice (Figure 10a).
Glomeruli showed similar numbers of CD4þ cells (rIgG,
0.15±0.04 c/gcs; anti-Tim-1, 0.13±0.07 c/gcs), macrophages
(rIgG, 0.31±0.04 c/gcs; anti-Tim-1, 0.26±0.03 c/gcs), and
neutrophils (rIgG, 0.28±0.02 c/gcs; anti-Tim-1, 0.22±0.05
c/gcs). Infiltrating interstitial CD4þ T cells were reduced
after anti-Tim-1 antibodies (rIgG, 0.47±0.08 c/hpf; anti-
Tim-1 0.37±0.02 c/hpf; Po0.05), but interstitial macro-
phages (rIgG, 0.62±0.07; anti-Tim-1, 0.58±0.02 c/hpf) and
neutrophils (rIgG, 0.51±0.09 c/hpf, anti-Tim-1, 0.45±0.05
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Figure 4 | Effects of anti-T-cell immunoglobulin mucin 1
(Tim-1) antibodies on CD4þ T-cell responses. Splenic CD4þ
cell apoptosis, proliferation, and cytokine production on day 14
were assessed by flow cytometric analysis of annexin-V binding,
bromodeoxyuridine (BrdU) uptake, and intracellular interferon-
gamma (IFN-g) and interleukin (IL)-17A. Results are expressed as
the percentage of CD4þ cells that were also BrdUþ (a), annexin-
Vþ (b), IFN-gþ (c), and IL-17Aþ (d). In comparison with rat IgG
(rIgG)-treated mice, anti-Tim-1 antibody–treated mice developed
less CD4þ cell proliferation (a) and apoptosis (b), with fewer
CD4þ cells positive for BrdU or annexin-V. The proportion of
CD4þ cells expressing IFN-g was significantly reduced (c), but
reductions in CD4þ cell IL-17A expression (d) did not reach
significance. PI, propidium iodide. *Po0.05.
Table 1 | Splenic T-cell transcription factor mRNA expression
14 days after the induction of glomerulonephritis
rIgG Anti-Tim-1
T-bet 14.6±0.3 8.8±0.3*
GATA3 2.1±0.3 7.5±1.3*
RORg 11.1±0.2 6.3±0.2**
Foxp3 2.9±0.6 3.9±0.9
Abbreviations: rIgG, rat IgG; Tim-1, T-cell immunoglobulin mucin 1.
Data are expressed as fold differences relative to normal mice without
glomerulonephritis. Anti-Tim-1 antibody–treated mice had reduced splenic mRNA
expression of T-bet and RORg and increased GATA3. *Po0.05, **Po0.005.
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c/hpf) were similar. Splenocyte cultures at day 6 (Figure 10b)
showed a trend to reduced IFN-g (rIgG, 1.6±0.8 ng/ml; anti-
Tim-1, 0.9±0.1 ng/ml) and IL-17A (rIgG, 143±63 pg/ml;
anti-Tim-1, 65±10 pg/ml) production in anti-Tim-1 anti-
body–treated mice, but IL-4 (rIgG, 6.2±4.9 pg/ml; anti-
Tim-1, 6.1±2.1 pg/ml) was unchanged (IL-10 waso20 pg/ml,
the limit of the assay’s detection). In the kidney, Tim-1þ
proximal tubules and intrarenal Tim-1 mRNA expression
were similar in both groups (rIgG, 20.1±2.5; anti-Tim-1,
18.1±1.7; Figure 10c).
DISCUSSION
Tim-1 (Kim-1) is expressed in both the immune system and
in injured renal tubules. The current studies tested the
hypothesis that Tim-1 promotes cell-mediated injury in
murine crescentic glomerulonephritis. Administering RMT1-
10, an antagonistic anti-Tim-1 antibody, reduced renal
injury. Systemic immune responses revealed that anti-Tim-
1 treatment reduced T-cell proliferation, and limited Th1 and
Th17 responses, but not Th2, humoral responses, or foxp3þ
cells. The antibody’s effects were primarily mediated by inhib-
iting autologous responses to sheep globulin, as heterologous
phase proteinuria (day 1) and early phase injury (day 6) were
unaffected. Tim-1 was expressed by intrarenal CD4þ T cells
in disease, suggesting an additional effect on effector T cells
locally.
Anti-Tim-1 affected immunity to the nephritogenic
antigen by selectively diminishing injurious T-cell subsets
that promote cell-mediated renal injury. Anti-Tim-1 anti-
bodies reduced both proliferation and apoptosis of splenic
CD4þ cells. Importantly, the CD4þ cell subsets (Th1 and
Th17) that promote cell-mediated responses were dimin-
ished, but those that limit cell-mediated injury (the Th2 and
Treg subsets) were not. Anti-Tim-1 antibodies limited Th1
responses (splenic T-bet mRNA, splenocyte IFN-g produc-
tion, and lower proportions of CD4þ cells expressing
IFN-g) and similar findings were evident when Th17
responses were examined (reduced RORg and IL-17A). Both
Th1 and Th17 effector cells can induce experimental
proliferative glomerulonephritis,23 and these subsets are
pathogenic in models similar to that used in the current
studies.24,25 However, subsets that are protective in experi-
mental crescentic glomerulonephritis, Th2 (refs 5, 6) and
Tregs,7 were not reduced by anti-Tim-1 antibodies. Splenic
GATA3 mRNA was increased, systemic IL-4 production was
unaffected, and the IgG1 subclass was increased. Similarly,
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proportions of foxp3þ cells and immune system foxp3
mRNA were not reduced by anti-Tim-1 treatment.
The impaired cellular response after anti-Tim-1 antibody
treatment resulted in less renal disease, with less histological
injury, proliferation, and apoptosis. Leukocyte numbers
were reduced (apart from foxp3þ cells that were increased),
with decreased IFN-g, IL-17A, and IL-1b mRNA. However,
mRNA for cytokines and transcription factors associated
with protective and anti-inflammatory responses (IL-4,
IL-10, and foxp3) were increased. Chemokines and adhesion
molecules, that have an important role in leukocyte
recruitment,26 were reduced by anti-Tim-1 treatment. There
was less intrarenal mRNA expression of the CD4þ Th1 cell
chemoattractants, CCL5 and CXCL9. However, anti-Tim-1
did not affect CXCL10 mRNA expression, redundant in this
model.27 CCL20, the only known ligand for CCR6 (expressed
on Th17 cells but important in Treg recruitment to the
kidney28) was unaffected, consistent with intact foxp3þ cell
recruitment to kidneys. Although CCL20 can recruit Th17
cells, generation of these cells in secondary lymphoid organs
was impaired by anti-Tim-1 antibodies, whereas generation
of Tregs was not. CCL2 mRNA (that attracts macrophages)
and the neutrophil chemokines CXCL1 and CXCL2 were
reduced. ICAM-1 is upregulated in mice with crescentic
nephritis, where it mediates leukocyte recruitment.29,30 In the
current studies, anti-Tim-1 antibodies reduced ICAM-1
glomerular and tubular expression.
The affects of inhibiting Tim-1 on immune responses in
this model, where disease is mediated by an immune
response to a planted foreign antigen, are similar to those
observed in allogeneic31 and autoimmune responses.21 Anti-
Tim-1 antibodies can have stimulatory or inhibitory actions,
depending on avidity and potentially the exact binding
sites.21,32 Although the monoclonal anti-Tim-1 antibodies
RMT1-10 (used in the current studies) and 3B3 are both
specific for Tim-1’s IgV domain, they have different effects
on T-cell responses, suggesting both positive and negative
co-stimulatory roles for Tim-1.21 The agonistic antibody
3B3 increased IFN-g and IL-17 secretion and exacerbated
experimental autoimmune encephalitis, whereas RMT1-10
(with a 17-fold lower avidity) limited Th1 and Th17
responses, promoted Th2 responses, and enhanced Treg
function.21,31 A recent paper has implicated Tim-1 in the
function of regulatory B cells in allogeneic responses.33
Although disease in the current model was unchanged in
B-cell–deficient mice,9 and effector responses were not
universally diminished by RMT1-10 in the current studies,
the role of regulatory B cells (and potentially Tim-1 on these
cells in glomerulonephritis) is an interesting area for future
study.
In addition to its roles in the immune system, Tim-1 (as
Kim-1) is expressed on injured tubulointerstitial cells, and in
the current studies the RMT1-10 antibody did bind to the
luminal surface of some tubular cells. However, several lines
of evidence imply that functional effects of RMT1-10 on
tubular cell Kim-1 are unlikely to have a major role in the
current studies. First, although RMT1-10 has antagonistic
effects on Tim-1 in T-cell responses, it does not affect
Tim-1–mediated binding of apoptotic cells,22 and a major
effect of Kim-1 in renal tubular cells is to allow binding to
apoptotic cells.20 Second, although renal Kim-1 may mediate
neutrophil infiltration as a ligand for LMIR5, RMT1-10 does
not block Tim-1–LMIR5 interactions.34 Third, in two recent
studies in acute tubulointerstitial injury,35,36 RMT1-10 did
not affect tubulointerstitial injury in mice lacking T cells and
B cells (Rag1/ mice). Fourth, although interstitial injury
is an important feature of progressive glomerulonephritis,
glomerular injury was reduced by RMT1-10, and Kim-1 is
not expressed by intrinsic glomerular cells. Lastly, although
renal Kim-1 protein was reduced after RMT1-10 treatment,
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Kim-1 mRNA was also decreased, implying that the reduced
Kim-1 seen is a marker for reduced injury, as opposed to the
changes being a direct effect of RMT1-10 on tubular cell
Kim-1. However, it remains possible that RMT1-10 affects
tubular cells, and we cannot rule out the possibility that some
of the diminution of interstitial injury observed at day 14
might be because of effects on tubular cell Tim-1.
In conclusion, the anti-Tim-1 antibody RMT1-10 protects
mice from proliferative and crescentic glomerulonephritis,
via effects on the Th1 and Th17 subsets, with substantial
reductions in proteinuria, crescent formation, and intrarenal
leukocyte infiltration.
MATERIALS AND METHODS
Experimental design
Male 8- to 10-week-old C57BL/6 mice (Monash Animal Services,
Melbourne, Australia) were used. Studies were approved by the
Monash University Animal Ethics Committee according to the
Australian National Health and Medical Research Council guide-
lines. Glomerulonephritis was induced by intravenous administra-
tion of sheep anti-mouse GBM antibodies, prepared as described
previously37 (27mg/mouse; day 0). Mice were intraperitoneally
injected with either 250 mg rat anti-mouse Tim-1 monoclonal
antibody RMT1-10 (ref. 21) (n¼ 8, grown and purified in house) or
protein G–purified rat IgG (n¼ 7) in 250 ml phosphate-buffered
saline every third day from days 0 to 12. Heterologous injury was
assessed 24 h after anti-GBM globulin injection by proteinuria.
In studies examining day 6 (the early autologous phase), mice
(n¼ 7 each group) were injected intravenously with anti-GBM
antibodies (14mg/mouse; day 0) and intraperitoneally injected with
10
IFN-γ mRNA IL-17A mRNA
IL-4 mRNA
IL-1β mRNA TNF mRNA
IL-10 mRNA
rlgG
Anti-Tim-1
IL-12p40 mRNA
Fo
ld
 in
cr
ea
se
Fo
ld
 in
cr
ea
se
Fo
ld
 in
cr
ea
se
10
20 4
2
0
*
*
**
*
5
0 0
5010
5
0
30
20
10
0 0
10
20
25
0
Figure 7 |Anti-T-cell immunoglobulin mucin 1 (Tim-1) antibodies reduce intrarenal proinflammatory cytokine gene expression in
glomerulonephritis. Cytokine gene expression was measured 14 days after injection of anti-GBM antibodies in mice treated with rat IgG
(rIgG) or anti-Tim-1 antibodies. IFN-g, IL-17A, and IL-1b expression were significantly reduced, reductions in IL-12p40 and tumor necrosis
factor (TNF) did not reach significance, and IL-4 and IL-10 mRNAs were increased after anti-Tim-1 antibody treatment. Expression levels were
normalized to the expression of 18S rRNA and expressed relative to saline-treated normal mice without nephritis. *Po0.05, **Po0.005.
Table 2 | Intrarenal chemokine mRNA expression 14 days
after the induction of glomerulonephritis
rIgG Anti-Tim-1 antibodies
CCL2/MCP-1 19.7±4.2 7.5±1.6*
CCL5/RANTES 9.1±2.2 5.4±1.3*
CCL20/LARC 109±36 99±29
CXCL1/KC 3.4±0.2 2.2±0.3*
CXCL2/MIP-2 1.7±0.6 0.7±0.2*
CXCL9/Mig 3.6±0.9 0.9±0.1*
CXCL10/IP-10 7.2±1.9 6.9±1.8
Abbreviations: rIgG, rat IgG; Tim-1, T-cell immunoglobulin mucin 1.
Data are expressed as fold differences relative to normal mice without nephritis.
Anti-Tim-1–treated mice had reduced intrarenal mRNA expression of CCL2, CCL5,
CXCL1, CXCL2, and CXCL9. *Po0.05.
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250mg anti-Tim-1 antibody or rIgG on days 0 and 3. Each end-
point was assessed in all mice from each group. To determine
whether Tim-1 is expressed on intrarenal CD4þ cells, mice were
injected with sheep anti-mouse GBM antibodies (without
RMT1-10 or rIgG) and kidneys digested for flow cytometric
evaluation of CD4þ cells at days 6 (n¼ 5) and 14 (n¼ 5). Normal
mice (n¼ 4) served as additional controls for some endpoints.
Results are expressed as mean±s.e.m. Unpaired t-test was used for
statistical analysis (GraphPad Prism; GraphPad Software, San
Diego, CA).
Assessment of renal injury
Renal histology was assessed on periodic acid-Schiff-stained,
formalin-fixed, 3 mm paraffin sections. Abnormalities included
crescent formation (X2 cell layers in Bowman’s space), segmental
proliferation, necrosis, hyalinosis, or capillary wall thickening (X50
glomeruli per mouse). Interstitial injury was scored semiquantita-
tively according to previously described criteria38 in 10 randomly
selected cortical areas per animal ( 200 magnification) using
a scale of 0–4, with ‘1’ being minimal and ‘4’ being severe
inflammation. Proteinuria was measured on urine collected over
24 h3 and serum and urine creatinine levels were measured by an
autoanalyzer.
Immunohistochemical analyses
Immunohistochemical staining for macrophages, CD4þ cells, and
Kim-1 was performed on 6 mm periodate lysine paraformaldehye–-
fixed sections using the ABC method, as described previously.39
Primary antibodies were FA/11 (rat anti-mouse CD68, macro-
phages), GK1.5 (rat anti-mouse CD4; American Type Culture
Collection, Manassas, VA), and rat anti-mouse Kim-1 (R&D
Systems, Minneapolis, MN). Ki-67þ cells, cleaved caspase-3þ
cells, foxp3þ cells, and neutrophils were identified in 4 mm
formalin-fixed sections with rat anti-mouse Ki-67 (Dako, Campbell-
field, Australia), rabbit anti-cleaved caspase-3 (Cell Signaling
Technology, Beverly, MA), rat anti-mouse foxp3 antibodies (FJK-
16s; eBioscience, San Diego, CA), and RB6-8C5 for neutrophils
(anti-Gr-1) using antigen retrieval. At least 50 glomeruli per mouse
were examined and results were expressed as c/gcs. At least 10
( 400) cortical interstitial fields (excluding perivascular areas) per
mouse were examined to determine cell numbers per hpf.40 ICAM-1
was identified in 4 mm frozen kidney sections.41 Intraglomerular and
tubular ICAM-1 expression was scored from 0 to 3, with 0
representing background staining and 3 representing strongly
positive staining in at least 20 glomeruli and 10 ( 400) cortical
interstitial fields per mouse. To assess RMT1-10’s binding to tubular
cells, rat IgG was detected on 4 mm frozen sections (preincubated
with 10% rabbit serum in 5% BSA/PBS) using Alexa Fluor
488–conjugated rabbit anti-rat antibodies (Invitrogen, Mount
Waverley, Australia; 1:150, with 10% mouse serum) in mice with
glomerulonephritis receiving no rIgG, nonimmune rIgG or RMT1-
10. Autofluorescence was quenched by immersing slides in Sudan
Black B in 70% ethanol. A normal mouse given rat anti-mouse
CD45 antibodies (that bind to splenic and renal leukocytes) was a
positive control.
Flow cytometric analyses
For assessment of apoptosis, proliferation, Tregs, and intracellular
cytokines by flow cytometry, spleens were obtained on days 6 and
14.42 CD4þ cell apoptosis was assessed by FITC-conjugated
annexin V (Roche Diagnostics, Castle Hill, Australia) and
propidium iodide (1mg/ml; Calbiochem, San Diego, CA). Results
were expressed as the percentage of CD4þ cells, as well as annexin-
Vþ propidium iodide-. For CD4þ cell proliferation, mice were
injected intraperitoneally with 1mg bromodeoxyuridine (Sigma) 48,
36, 24, and 12 h before the day 14 time point. An anti-mouse foxp3
staining set (eBioscience) was used for foxp3þ cells.7 For intra-
cellular cytokines, cells were stained with FITC-conjugated anti-
IL-17A and phycoerythrin-conjugated anti-IFN-g (BD Biosciences,
North Ryde, Australia). For intrarenal CD4þ cell Tim-1 expression,
kidneys from normal mice, and from mice 6 and 14 days after anti-
GBM antibodies,7 were digested and assessed using Pacific Blue–-
conjugated anti-CD45, APC-Cy7–conjugated CD4, APC-conjugated
CD44 (BD Biosciences), and Alexa Fluor 488–conjugated anti-
Tim-1 antibodies (clone RMT1-10). Isotype-matched irrelevant
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monoclonal antibodies, single-color controls, and fluorescence
minus one cocktails were used as controls.
Renal and splenic mRNA expression
Splenic and renal RNA from each mouse was extracted with TRIzol
(Invitrogen). Real-time PCR was performed on a Rotor Gene RG-
3000 (Corbett Research, Mortlake, Australia) using FastStart DNA
master Sybr Green I (Roche Diagnostics) in the case of IFN-g, IL-1b,
IL-12p40, tumor necrosis factor, ICAM-1, CCL1, CCL2, CCL5,
CCL20, CXCL1, CXCL2, CXCL9, CXCL10, T-bet, GATA3, RORg,
and foxp3 mRNA. For Kim-1, IL-4, IL-17A, and IL-10 detection,
TaqMan predesigned real-time PCR assays were used (Applied
Biosystems, Foster City, CA). Results were standardized to the
housekeeping gene 18S and expressed as fold differences relative to
mice without glomerulonephritis.
Splenocyte cytokine production, urinary Kim-1 levels, and
anti-sheep antibody titers
Concentrations of IFN-g, IL-4, IL-10, and IL-17A in supernatants
on day 6 and 14 and Kim-1 in urine on days 0, 1, 6, and 14
were measured by enzyme-linked immunoassay, as described
previously.25 Antibodies were rat anti-mouse IFN-g (R4-6A2),
biotinylated rat anti-mouse IFN-g (XMG1.2), rat anti-mouse IL-4
(11B11), biotinylated rat anti-mouse IL-4 (BVD6), rat anti-mouse
IL-10, biotinylated rat anti-mouse IL-10 (both BD Biosciences),
anti-mouse IL-17A, biotinylated rat anti-mouse IL-17A (both
eBioscience), anti-mouse Tim-1 antibody (clone 222414), and
biotinylated goat anti-mouse Tim-1 (both R&D Systems). Titers
of mouse anti-sheep globulin IgG (1:50–1:1600 dilutions), IgG1
(1:50), and IgG3 (1:50) were assessed by enzyme-linked immuno-
assay on sera collected at the end of experiments.43
Kim-1 western blotting
Proteins were extracted by homogenization of day 14 kidneys in
T-PER protein extraction reagent (Pierce, Rockford, IL). Equal
amounts of protein were loaded for nonreducing SDS-gel electro-
phoresis, electroblotted onto polyvinylidene fluoride membranes,
then incubated with blocking buffer, primary antibodies (anti-b-
actin antibody, Santa Cruz, St. Louis, MO and anti-mouse Tim-1
antibody; clone 222414), and horseradish peroxidase-conjugated
secondary antibodies (R&D Systems). Antigens were revealed and
visualized with an enhanced chemiluminescence detection system
(Amersham Biosciences, Piscataway, NJ). Densities were deter-
mined using a lumino image analyzer (LAS-4000, Fuji Photo Film,
Tokyo, Japan) and results were expressed as a proportion of b-actin
density.
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Figure 9 |Renal kidney injury molecule-1 (Kim-1) in glomerulonephritis. (a) No Kim-1 is present in normal kidneys. (b) On day 14
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